Theriva Biologics, Inc. (TOVX) stock forecast & analysis
0.1840
NYSE American · USD
Up: +0.0135, +7.9%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.1500
- Previous close
- 0.1705
- Day range
- 0.1361 – 0.1904
- 52-week range
- 0.1361 – 0.4900
- Volume (shares)
- 91.20M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 45.89M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 1.26
- Market cap
- 8.44M
Market Scanner’s AI analysis of Theriva Biologics, Inc. (TOVX), updated November 2026: Theriva Biologics' recent analyses covered its divestiture of SYN-004, clinical trial updates for VCN-01, and ongoing financial performance.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Theriva Biologics, Inc. (TOVX) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
Theriva Biologics' recent analyses covered its divestiture of SYN-004, clinical trial updates for VCN-01, and ongoing financial performance.
Recent analyses for Theriva Biologics (TOVX) examined the company's financial performance, including revenue and net losses over several years, alongside technical trading indicators suggesting bearish momentum. The reports also detailed recent corporate actions such as the sale of its SYN-004 portfolio and clinical trial updates for VCN-01.
TOVX news & sentiment
News coverage highlighted Theriva Biologics' recent divestiture of a key asset and updates on its VCN-01 clinical trials. Social media discussion was not covered in the provided notes.
TOVX technical picture
TOVX is trading below its key moving averages, indicating a bearish trend across multiple timeframes. Momentum indicators suggest negative short-term and long-term trends, though some readings indicate potential oversold conditions.
Fundamentals
Theriva Biologics reported $300,000 in revenue for the quarter ending March 31, 2026. The company has consistently reported net losses and negative operating income across multiple fiscal years, with a Return on Equity (TTM) of -101.9% as of June 30, 2026.
Factors discussed — upside
- RSI below oversold threshold indicating potential rebound
- Price below lower Bollinger Band suggesting short-term oversold conditions
Factors discussed — risks
- Trading below 50-day and 200-day simple moving averages
- 10-day EMA below current price indicating negative short-term momentum
- Very low MFI suggesting significant selling pressure and weak buying interest
- MACD below zero indicating bearish momentum
- Consistent net losses reported over multiple fiscal years
- Clinical trial progress
- Divestiture of assets
- Financial performance
- Technical indicators
Summary updated .
TOVX technical indicators
Common technical indicators for TOVX, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.22 | Price below |
| 10-day exponential moving average | 0.19 | Price below |
| Relative strength index (14-day) | 34.64 | Neutral |
| MACD line (12/26/9) | -0.0124 | Below its signal line |
| Bollinger bands (20-day, 2σ) | 0.17 – 0.24 | Price inside the bands |
Analyses
Recent TOVX.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-03 TOVX.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Theriva Biologics, Inc.?
- The analyses noted that the Relative Strength Index (RSI) is below the oversold threshold, suggesting a potential price rebound, and that the price trading below the lower Bollinger Band indicates short-term oversold conditions.
- What are the risks for Theriva Biologics, Inc.?
- The company's stock is trading below key moving averages, signaling bearish medium- and long-term trends, with short-term momentum also negative. Additionally, a very low Money Flow Index (MFI) suggests significant selling pressure and weak buying interest, while the MACD indicates bearish momentum.
- Is Theriva Biologics, Inc. bullish or bearish?
- Recent AI analyses of Theriva Biologics, Inc. examined factors on both sides. Discussed upside: The analyses noted that the Relative Strength Index (RSI) is below the oversold threshold, suggesting a potential price rebound, and that the price trading below the lower Bollinger Band indicates short-term oversold conditions. Discussed risks: The company's stock is trading below key moving averages, signaling bearish medium- and long-term trends, with short-term momentum also negative. Additionally, a very low Money Flow Index (MFI) suggests significant selling pressure and weak buying interest, while the MACD indicates bearish momentum. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Theriva Biologics, Inc.?
- News coverage highlighted Theriva Biologics' recent divestiture of a key asset and updates on its VCN-01 clinical trials. Social media discussion was not covered in the provided notes.
- How does Market Scanner analyse Theriva Biologics, Inc.?
- Every analysis of Theriva Biologics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Theriva Biologics, Inc.?
The analyses noted that the Relative Strength Index (RSI) is below the oversold threshold, suggesting a potential price rebound, and that the price trading below the lower Bollinger Band indicates short-term oversold conditions.
What are the risks for Theriva Biologics, Inc.?
The company's stock is trading below key moving averages, signaling bearish medium- and long-term trends, with short-term momentum also negative. Additionally, a very low Money Flow Index (MFI) suggests significant selling pressure and weak buying interest, while the MACD indicates bearish momentum.
Is Theriva Biologics, Inc. bullish or bearish?
Recent AI analyses of Theriva Biologics, Inc. examined factors on both sides. Discussed upside: The analyses noted that the Relative Strength Index (RSI) is below the oversold threshold, suggesting a potential price rebound, and that the price trading below the lower Bollinger Band indicates short-term oversold conditions. Discussed risks: The company's stock is trading below key moving averages, signaling bearish medium- and long-term trends, with short-term momentum also negative. Additionally, a very low Money Flow Index (MFI) suggests significant selling pressure and weak buying interest, while the MACD indicates bearish momentum. These are descriptive observations, not a recommendation.
What is the latest sentiment on Theriva Biologics, Inc.?
News coverage highlighted Theriva Biologics' recent divestiture of a key asset and updates on its VCN-01 clinical trials. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Theriva Biologics, Inc.?
Every analysis of Theriva Biologics, Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh TOVX.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.